# Neogen Corp: financial statements, quarterly

NEOG · Nasdaq · CIK 711377 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31

Pages: [Overview](/companies/neog.md) · [Financials](/companies/neog/financials.md) · [Filings](/companies/neog/filings.md) · [Insiders](/companies/neog/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/neog/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [230](/filings/0000950170-25-005818.md) | [229](/filings/0000950170-25-052497.md) | [237 d](/filings/0001193125-26-326092.md) | [217](/filings/0001193125-25-235720.md) | [231](/filings/0001193125-26-007682.md) | [221](/filings/0001193125-26-149599.md) | [226 d](/filings/0001193125-26-326092.md) | [209](/filings/0001193125-26-416954.md) | [225](/filings/0001193125-26-007682.md) | [211](/filings/0001193125-26-149599.md) | [225 d](/filings/0001193125-26-326092.md) | [223](/filings/0001193125-26-416954.md) |
| Cost of revenue | $m | [113](/filings/0000950170-25-005818.md) | [112](/filings/0000950170-25-052497.md) | [123 d](/filings/0000950170-25-100064.md) | [112](/filings/0001193125-25-235720.md) | [118](/filings/0001193125-26-007682.md) | [111](/filings/0001193125-26-149599.md) | [133 d](/filings/0000950170-25-100064.md) | [114](/filings/0001193125-26-416954.md) | [118](/filings/0001193125-26-007682.md) | [112](/filings/0001193125-26-149599.md) | [118 d](/filings/0001193125-26-326092.md) | [117](/filings/0001193125-26-416954.md) |
| Gross profit | $m | [117](/filings/0000950170-25-005818.md) | [117](/filings/0000950170-25-052497.md) | [113 d](/filings/0001193125-26-326092.md) | [105](/filings/0001193125-25-235720.md) | [113](/filings/0001193125-26-007682.md) | [110](/filings/0001193125-26-149599.md) | [92.9 d](/filings/0001193125-26-326092.md) | [95.0](/filings/0001193125-26-416954.md) | [107](/filings/0001193125-26-007682.md) | [99.0](/filings/0001193125-26-149599.md) | [108 d](/filings/0001193125-26-326092.md) | [106](/filings/0001193125-26-416954.md) |
| Research and development | $m | [5.8](/filings/0000950170-25-005818.md) | [4.9](/filings/0000950170-25-052497.md) | [5.2 d](/filings/0001193125-26-326092.md) | [5.2](/filings/0001193125-25-235720.md) | [5.1](/filings/0001193125-26-007682.md) | [4.5](/filings/0001193125-26-149599.md) | [6.3 d](/filings/0001193125-26-326092.md) | [5.1](/filings/0001193125-26-416954.md) | [4.6](/filings/0001193125-26-007682.md) | [3.8](/filings/0001193125-26-149599.md) | [4.9 d](/filings/0001193125-26-326092.md) | [6.5](/filings/0001193125-26-416954.md) |
| Operating income | $m | [14.5](/filings/0000950170-25-005818.md) | [12.0](/filings/0000950170-25-052497.md) | [13.0 d](/filings/0001193125-26-326092.md) | [2.3](/filings/0001193125-25-235720.md) | [(457)](/filings/0001193125-26-007682.md) | [5.4](/filings/0001193125-26-149599.md) | [(611) d](/filings/0001193125-26-326092.md) | [(16.1)](/filings/0001193125-26-416954.md) | [(5.4)](/filings/0001193125-26-007682.md) | [(3.3)](/filings/0001193125-26-149599.md) | [3.1 d](/filings/0001193125-26-326092.md) | [(1.8)](/filings/0001193125-26-416954.md) |
| Interest expense | $m | [10.3](/filings/0000950170-24-003320.md) | [10.5](/filings/0000950170-24-042952.md) | [10.8 d](/filings/0000950170-25-100064.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.3)](/filings/0000950170-25-005818.md) | [(3.8)](/filings/0000950170-25-052497.md) | [(1.0) d](/filings/0001193125-26-326092.md) | [(3.0)](/filings/0001193125-25-235720.md) | [(20.3)](/filings/0001193125-26-007682.md) | [1.2](/filings/0001193125-26-149599.md) | [(19.0) d](/filings/0001193125-26-326092.md) | [7.5](/filings/0001193125-26-416954.md) | [(4.4)](/filings/0001193125-26-007682.md) | [(3.3)](/filings/0001193125-26-149599.md) | [(0.8) d](/filings/0001193125-26-326092.md) | [(3.0)](/filings/0001193125-26-416954.md) |
| Net income | $m | [(3.5)](/filings/0000950170-25-005818.md) | [(2.0)](/filings/0000950170-25-052497.md) | [(5.4) d](/filings/0001193125-26-326092.md) | [(12.6)](/filings/0001193125-25-235720.md) | [(456)](/filings/0001193125-26-007682.md) | [(10.9)](/filings/0001193125-26-149599.md) | [(612) d](/filings/0001193125-26-326092.md) | [36.3](/filings/0001193125-26-416954.md) | [(15.9)](/filings/0001193125-26-007682.md) | [(17.0)](/filings/0001193125-26-149599.md) | [(11.3) d](/filings/0001193125-26-326092.md) | [(11.9)](/filings/0001193125-26-416954.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0000950170-25-005818.md) | [(0.01)](/filings/0000950170-25-052497.md) | not reported | [(0.06)](/filings/0001193125-25-235720.md) | [(2.10)](/filings/0001193125-26-007682.md) | [(0.05)](/filings/0001193125-26-149599.md) | not reported | [0.17](/filings/0001193125-26-416954.md) | [(0.07)](/filings/0001193125-26-007682.md) | [(0.08)](/filings/0001193125-26-149599.md) | not reported | [(0.05)](/filings/0001193125-26-416954.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0000950170-25-005818.md) | [(0.01)](/filings/0000950170-25-052497.md) | not reported | [(0.06)](/filings/0001193125-25-235720.md) | [(2.10)](/filings/0001193125-26-007682.md) | [(0.05)](/filings/0001193125-26-149599.md) | not reported | [0.17](/filings/0001193125-26-416954.md) | [(0.07)](/filings/0001193125-26-007682.md) | [(0.08)](/filings/0001193125-26-149599.md) | not reported | [(0.05)](/filings/0001193125-26-416954.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [206](/filings/0000950170-24-003320.md) | [161](/filings/0000950170-24-042952.md) | [171](/filings/0000950170-25-100064.md) | [120](/filings/0000950170-24-114022.md) | [140](/filings/0000950170-25-005818.md) | [128](/filings/0000950170-25-052497.md) | [129](/filings/0001193125-26-326092.md) | [139](/filings/0001193125-25-235720.md) | [145](/filings/0001193125-26-007682.md) | [160](/filings/0001193125-26-149599.md) | [186](/filings/0001193125-26-416954.md) | [172](/filings/0001193125-26-416954.md) |
| Current assets | $m | [624](/filings/0000950170-24-003320.md) | [602](/filings/0000950170-24-042952.md) | [589](/filings/0000950170-25-100064.md) | [541](/filings/0000950170-24-114022.md) | [570](/filings/0000950170-25-005818.md) | [552](/filings/0000950170-25-052497.md) | [577](/filings/0001193125-26-326092.md) | [524](/filings/0001193125-25-235720.md) | [575](/filings/0001193125-26-007682.md) | [590](/filings/0001193125-26-149599.md) | [605](/filings/0001193125-26-416954.md) | [583](/filings/0001193125-26-416954.md) |
| Total assets | $m | [4,602](/filings/0000950170-25-005818.md) | [4,582](/filings/0000950170-25-052497.md) | [4,549](/filings/0000950170-25-100064.md) | [4,503](/filings/0000950170-24-114022.md) | [4,054](/filings/0000950170-25-005818.md) | [4,036](/filings/0000950170-25-052497.md) | [3,444](/filings/0001193125-26-326092.md) | [3,378](/filings/0001193125-26-416954.md) | [3,360](/filings/0001193125-26-007682.md) | [3,359](/filings/0001193125-26-149599.md) | [3,346](/filings/0001193125-26-416954.md) | [3,303](/filings/0001193125-26-416954.md) |
| Current liabilities | $m | [177](/filings/0000950170-24-003320.md) | [158](/filings/0000950170-24-042952.md) | [154](/filings/0000950170-25-100064.md) | [123](/filings/0000950170-24-114022.md) | [151](/filings/0000950170-25-005818.md) | [141](/filings/0000950170-25-052497.md) | [174](/filings/0001193125-26-326092.md) | [146](/filings/0001193125-25-235720.md) | [147](/filings/0001193125-26-007682.md) | [151](/filings/0001193125-26-149599.md) | [158](/filings/0001193125-26-416954.md) | [150](/filings/0001193125-26-416954.md) |
| Total liabilities | $m | [1,455](/filings/0000950170-24-003320.md) | [1,436](/filings/0000950170-24-042952.md) | [1,405](/filings/0000950170-25-100064.md) | [1,368](/filings/0000950170-24-114022.md) | [1,385](/filings/0000950170-25-005818.md) | [1,376](/filings/0000950170-25-052497.md) | [1,373](/filings/0001193125-26-326092.md) | [1,260](/filings/0001193125-25-235720.md) | [1,255](/filings/0001193125-26-007682.md) | [1,257](/filings/0001193125-26-149599.md) | [1,253](/filings/0001193125-26-416954.md) | [1,217](/filings/0001193125-26-416954.md) |
| Long-term debt | $m | [887](/filings/0000950170-24-003320.md) | [888](/filings/0000950170-24-042952.md) | [888](/filings/0000950170-25-100064.md) | [889](/filings/0000950170-24-114022.md) | [890](/filings/0000950170-25-005818.md) | [891](/filings/0000950170-25-052497.md) | [875](/filings/0001193125-26-326092.md) | [793](/filings/0001193125-25-235720.md) | [793](/filings/0001193125-26-007682.md) | [793](/filings/0001193125-26-149599.md) | [794](/filings/0001193125-26-416954.md) | [774](/filings/0001193125-26-416954.md) |
| Current portion of debt | $m | [2.6](/filings/0000950170-24-003320.md) | [2.5](/filings/0000950170-24-042952.md) | [2.4](/filings/0000950170-25-100064.md) | not reported | not reported | not reported | [19.3](/filings/0001193125-26-326092.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-26-326092.md) | not reported |
| Shareholders' equity | $m | [3,148](/filings/0000950170-24-003320.md) | [3,146](/filings/0000950170-24-042952.md) | [3,144](/filings/0000950170-25-100064.md) | [3,135](/filings/0000950170-24-114022.md) | [2,669](/filings/0000950170-25-005818.md) | [2,660](/filings/0000950170-25-052497.md) | [2,071](/filings/0001193125-26-326092.md) | [2,119](/filings/0001193125-25-235720.md) | [2,104](/filings/0001193125-26-007682.md) | [2,102](/filings/0001193125-26-149599.md) | [2,093](/filings/0001193125-26-416954.md) | [2,086](/filings/0001193125-26-416954.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [15.7 d](/filings/0000950170-25-005818.md) | [(30.2) d](/filings/0000950170-25-052497.md) | [26.8 d](/filings/0001193125-26-326092.md) | [(17.9)](/filings/0001193125-25-235720.md) | [40.3 d](/filings/0001193125-26-007682.md) | [19.5 d](/filings/0001193125-26-149599.md) | [16.4 d](/filings/0001193125-26-326092.md) | [10.8](/filings/0001193125-26-416954.md) | [19.5 d](/filings/0001193125-26-007682.md) | [22.7 d](/filings/0001193125-26-149599.md) | [30.2 d](/filings/0001193125-26-326092.md) | [12.9](/filings/0001193125-26-416954.md) |
| Capital expenditure | $m | [24.4 d](/filings/0000950170-25-005818.md) | [32.1 d](/filings/0000950170-25-052497.md) | [24.2 d](/filings/0001193125-26-326092.md) | [38.4](/filings/0001193125-25-235720.md) | [17.2 d](/filings/0001193125-26-007682.md) | [32.9 d](/filings/0001193125-26-149599.md) | [16.1 d](/filings/0001193125-26-326092.md) | [24.0](/filings/0001193125-26-416954.md) | [11.7 d](/filings/0001193125-26-007682.md) | [11.6 d](/filings/0001193125-26-149599.md) | [4.0 d](/filings/0001193125-26-326092.md) | [8.2](/filings/0001193125-26-416954.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-11-30) | Q3 FY2023 (2023-02-28) | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [216](/filings/0000950170-24-003320.md) | [216](/filings/0000950170-24-042952.md) | [217](/filings/0000950170-24-114022.md) | [216](/filings/0000950170-25-005818.md) | [217](/filings/0000950170-25-052497.md) | [217](/filings/0001193125-25-235720.md) | [217](/filings/0001193125-26-007682.md) | [217](/filings/0001193125-26-149599.md) | [217](/filings/0001193125-26-416954.md) | [217](/filings/0001193125-26-007682.md) | [218](/filings/0001193125-26-149599.md) | [218](/filings/0001193125-26-416954.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 218,306,034 at 2026-08-31, from the cover of the [10-Q filed 2026-10-07](/filings/0001193125-26-416954.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.